-
1 Comment
Misonix, Inc is currently in a long term uptrend where the price is trading 30.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.1.
Misonix, Inc's total revenue sank by 7.4% to $18M since the same quarter in the previous year.
Its net income has increased by 75.2% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 81.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Misonix, Inc gets an overall score of 4/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US6048711039 |
Sector | Healthcare |
Industry | Medical Devices |
Beta | 1.35 |
---|---|
PE Ratio | None |
Dividend Yield | 0.0% |
Market Cap | 462M |
Target Price | 28 |
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator, which is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system that provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York. As of October 29, 2021, Misonix, Inc. operates as a subsidiary of Bioventus Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MSON using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025